Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31145846 | 1.00 | HTT (0.47) | HTTHSD17B10NOS3NOS2LOXL2 | |
| SCHEMBL31146149 | 0.75 | NR4A2 (0.32) | HTTHSD17B10 | |
| SCHEMBL29954308 | 0.74 | CCR1 (0.41) | HTTHSD17B10NOS3NOS2LOXL2 | |
| SCHEMBL8131114 | 0.74 | NOS2 (0.37) | NOS3NOS2 | |
| SCHEMBL157196 | 0.74 | HTT (0.50) | HTTHSD17B10NOS3NOS2LOXL2 | |
| SCHEMBL31184838 | 0.72 | NOS3 (0.35) | HTTNOS3NOS2 | |
| SCHEMBL29952573 | 0.72 | NOS3 (0.35) | HTTNOS3NOS2 | |
| SCHEMBL529516 | 0.72 | ALDH1A1 (0.38) | HSD17B10 | |
| SCHEMBL30937638 | 0.72 | ALDH1A1 (0.38) | HSD17B10 | |
| SCHEMBL16992858 | 0.72 | HTT (0.49) | HTTHSD17B10NOS3NOS2LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299188-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2889291-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299188-A1 | HETEROCYCLIC COMPOUND | PTGIS, LIPG, FEN1 | HTT 3357/4885HSD17B10 356/4885NOS3 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.